Good decisions require good information
Find hidden gems and smart strategies from top experts when you join Seeking Alpha.
SYRS Syros Pharmaceuticals, Inc.Stock Price & Overview
$5.10
Charts
Quant Ranking
SYRS Analysis
SYRS News
Latest Headlines
Ratings Summary
SYRS Company Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
SYRS Revenue
SYRS Earnings Per Share
Earnings Estimates
Earnings Revisions
Rating:
Valuation
Rating:
Growth
Rating:
Profitability
Rating:
Momentum
Rating:
52 Week Range
Capital Structure
Trading Data
Dividends
SYRS Ownership
SYRS Peers
Risk
Technicals
SYRS Transcripts
Investor Presentations
SYRS SEC Filings
Press Releases
SYRS Income Statement
SYRS Balance Sheet
SYRS Cash Flow Statement
SYRS Long Term Solvency
Discover More
You may be interested in: